These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Anti-RANKL monoclonal antibody Denosumab (AMG162)].
    Author: Sugimoto T.
    Journal: Clin Calcium; 2011 Jan; 21(1):46-51. PubMed ID: 21187593.
    Abstract:
    Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL) which blocks its binding to RANK, inhibiting the development and activity of osteoclasts, followed by suppression of bone resorption. Denosumb given subcutaneously twice yearly for 3 years was associated with a reduction in the risk of vertebral, nonvertebral and hip fractures but not with serious adverse events in women with osteoporosis. New horizon would be brought about by Denosumab, new molecular targeting pharmaceutics in the treatment of osteoporosis as well as rheumatoid arthritis and metastatic bone diseases.
    [Abstract] [Full Text] [Related] [New Search]